Rigel Pharmaceuticals, Inc.

NasdaqGS:RIGL Stock Report

Market Cap: US$390.5m

Rigel Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

Rigel Pharmaceuticals has been growing earnings at an average annual rate of 7.7%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 7.1% per year.

Key information

7.7%

Earnings growth rate

8.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate7.1%
Return on equityn/a
Net Margin2.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop

Dec 20
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) 28% Price Drop

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Nov 08
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Oct 10

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Sep 25
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Jul 30
There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Jul 24

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01
Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Oct 25
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib

Oct 10

Rigel Pharma adds ~7% to reach over two month high

Aug 18

Rigel rises 17% on strong Q2 result

Aug 03

Rigel Pharmaceuticals: A Status Check

May 31

Revenue & Expenses Breakdown

How Rigel Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:RIGL Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2415741100
30 Jun 24130-141080
31 Mar 24119-201060
31 Dec 23116-251060
30 Sep 23129-241110
30 Jun 23121-381120
31 Mar 23125-451130
31 Dec 22116-591120
30 Sep 2286-831050
30 Jun 2287-851020
31 Mar 2277-85970
31 Dec 21139-18920
30 Sep 21138-15890
30 Jun 21136-8840
31 Mar 21131-11800
31 Dec 20109-30770
30 Sep 20106-28730
30 Jun 20108-25740
31 Mar 20102-28730
31 Dec 1959-67750
30 Sep 1982-46780
30 Jun 1966-59780
31 Mar 1957-64760
31 Dec 1845-70700
30 Sep 187-100630
30 Jun 183-93530
31 Mar 181-87440
31 Dec 174-78380
30 Sep 177-68300
30 Jun 1710-73270
31 Mar 1719-67240
31 Dec 1620-69210
30 Sep 1626-66180
30 Jun 1635-50180
31 Mar 1632-51180
31 Dec 1529-51180
30 Sep 1529-61200
30 Jun 1516-75200
31 Mar 1510-87220
31 Dec 148-91230
30 Sep 146-85200
30 Jun 146-88200
31 Mar 147-86200

Quality Earnings: RIGL has high quality earnings.

Growing Profit Margin: RIGL became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: RIGL has become profitable over the past 5 years, growing earnings by 7.7% per year.

Accelerating Growth: RIGL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: RIGL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).

Return on Equity

High ROE: RIGL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/27 12:45
End of Day Share Price 2025/01/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rigel Pharmaceuticals, Inc. is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James BirchenoughBarclays
Clarence PowellBMO Capital Markets Equity Research
James BirchenoughBMO Capital Markets Equity Research